Cfra set a GBX 1,650 ($21.56) price objective on GlaxoSmithKline (LON:GSK) in a research note released on Thursday morning. The firm currently has a neutral rating on the stock.
A number of other analysts have also issued reports on the stock. Barclays restated an overweight rating on shares of GlaxoSmithKline in a research note on Monday, September 24th. Societe Generale set a GBX 1,000 ($13.07) price target on shares of GlaxoSmithKline and gave the stock a sell rating in a research note on Monday, September 10th. UBS Group restated a buy rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a research note on Thursday, September 27th. Jefferies Financial Group set a GBX 1,775 ($23.19) price target on shares of GlaxoSmithKline and gave the stock a buy rating in a research note on Thursday, August 16th. Finally, Shore Capital restated a buy rating on shares of GlaxoSmithKline in a research note on Monday, September 10th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline has an average rating of Hold and a consensus target price of GBX 1,521.27 ($19.88).
Shares of LON:GSK opened at GBX 1,480 ($19.34) on Thursday. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).
The firm also recently announced a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 15th. This represents a yield of 1.26%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.